Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878506 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL765515 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL10001914 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14255653 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL19238714 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL1365176 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7953922 | 1.00 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL4728286 | 0.98 | SLC6A3 (0.55) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL729968 | 0.87 | SLC6A4 (0.55) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL734761 | 0.87 | SLC6A4 (0.55) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2008013856-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL -3-AZABICYCLO[3.1.0 ] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013856-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL -3-AZABICYCLO[3.1.0 ] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A3 92/4885SLC6A4 221/4885SLC6A2 276/4885 |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | SLC6A3 982/4885SLC6A4 2230/4885SLC6A2 3023/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A3 92/4885SLC6A4 221/4885SLC6A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.